Some changes to PBS conditions for Zytiga (abiraterone) before chemotherapy with Taxotere (docetaxel)

[Admin]

Jim Marshall (not a doctor) said ...

Some changes to the PBS rules on Zytiga before chemotherapy with Taxotere (docetaxel) mean that:

• Men deemed unsuitable for docetaxel may have PBS-subsidised Zytiga. 
• Men who have had PBS-subsidised Zytiga may have docetaxel later if they need it.
• PBS-subsidised Zytiga will not generally be available for men who have had Xtandi (enzalutamide).

Zytiga (abiraterone) before chemotherapy with Taxotere (docetaxel) is still not covered by the PBS.

... end Jim

 

UPDATED AUTHORITY REQUIREMENT 

Zytiga  will be reimbursed (Authority required) for castration resistant metastatic carcinoma of the prostate, with the following restrictions: 

• Treatment must be in combination with prednisone or prednisolone 

• Treatment must not be used in combination with chemotherapy 

• Patients must have failed treatment with docetaxel due to resistance or intolerance, or be deemed unsuitable for docetaxel treatment on the basis of demonstrated or predicted intolerance to docetaxel

• Patients must have a WHO performance status of 2 or less 

• Patients must not receive PBS-subsidised Zytiga  if progressive disease develops while on Zytiga  

• Patients must not have received prior treatment with enzalutamide or must have developed intolerance to enzalutamide of a severity necessitating permanent treatment withdrawal.

 

Jim Marshall (not a doctor) said ...

And 'no PBS docetaxel' after Zytiga' rule has been removed.

... end Jim

Patients who have received treatment with Zytiga  through the PBS will now be eligible for PBS-subsidised docetaxel if required at a later date. Previously, patients were unable to receive PBS-subsidised docetaxel if they had already received PBS-subsidised Zytiga .